Karolina Faysman, RN, MSN, AOCNP, DNPc, highlights efficacy, safety, and patient-reported outcomes from the phase 2 AGAVE-201 trial evaluating axatilimab for chronic graft-versus-host disease.

Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease (AGAVE-201)

Rapid Readouts

Rapid Readouts is a video program featuring leading experts who provide in-depth reviews of the most pivotal and practice-changing data that have been unveiled at recent medical oncology conferences. In each video, top oncologists in their specialty present slides and posters from these annual symposiums and meetings, while highlighting the ever-changing landscape of treatment choices for patient management.